Renewed Reality
Amy Emerson has a long history working with pharmaceutical companies in immunology, oncology and vaccines, eventually joining the team at the Multidisciplinary Association for Psychedelic Studies (MAPS). In her current role as the CEO of MAPS’ Public Benefit Corporation (MAPS PBC), she oversees the strategy and implementation of the MDMA-assisted psychotherapy research program. Emerson works closely with Dr. Berra Yazar-Klosinski, the deputy director of MAPS and the chief scientific officer of MAPS PBC, who has played a key role in the development of MDMA-assisted psychotherapy and other psychedelic compounds.
Along with moderator Dr. Daniel Kelly, a neurosurgeon and director of Pacific Neuroscience Institute (PNI) who has been a driving force behind the psychedelics research and treatment program at PNI, Emerson and Yazar-Klosinski will speak to the science and research behind this powerful new method of therapy and what it could mean for the future of mental health.